mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0057 |
0.9 |
mRNA |
MK-2206 |
CTRPv2 |
pan-cancer |
AAC |
-0.0058 |
0.9 |
mRNA |
erlotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.006 |
0.9 |
mRNA |
BRD-K34485477 |
CTRPv2 |
pan-cancer |
AAC |
0.012 |
0.9 |
mRNA |
BRD-A02303741 |
CTRPv2 |
pan-cancer |
AAC |
-0.0058 |
0.9 |
mRNA |
Compound 1541A |
CTRPv2 |
pan-cancer |
AAC |
0.0057 |
0.9 |
mRNA |
BRD-K58730230 |
CTRPv2 |
pan-cancer |
AAC |
0.011 |
0.9 |
mRNA |
ciclosporin |
CTRPv2 |
pan-cancer |
AAC |
0.0053 |
0.9 |
mRNA |
BRD-A02303741:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0053 |
0.9 |
mRNA |
BRD-K13999467 |
CTRPv2 |
pan-cancer |
AAC |
0.005 |
0.9 |